Michael Singer
About
In The Last Decade
Michael Singer
108 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Ophthalmology 1.9k
- Molecular Biology 1.6k
- Radiology, Nuclear Medicine and Imaging 1.4k
- Immunology 208
- Genetics 199
Countries citing papers authored by Michael Singer
This map shows the geographic impact of Michael Singer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Singer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Singer more than expected).
Fields of papers citing papers by Michael Singer
This network shows the impact of papers produced by Michael Singer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Singer. The network helps show where Michael Singer may publish in the future.
Co-authorship network of co-authors of Michael Singer
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Singer. A scholar is included among the top collaborators of Michael Singer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Singer. Michael Singer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 6 | |
| 4 | 3 | |
| 5 | Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study | 8 |
| 6 | 11 | |
| 7 | 47 | |
| 8 | Evaluation of a combined ultra-wide field SLO with SD OCT | 1 |
| 9 | Treatment burden associated with intravitreal injections in the real world: PALADIN Phase 4 trial with fluocinolone acetonide 0.2 µg/day | 1 |
| 10 | 20 | |
| 11 | 53 | |
| 12 | Long-term Visual Outcomes by Baseline Subgroup Characteristics of Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration after the VIEW1 Study | 1 |
| 13 | Modeling Flow Past a Tilted Vena Cava Filter | 1 |
| 14 | HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results | 6 |
| 15 | 44 | |
| 16 | 200 | |
| 17 | 268 | |
| 18 | 6 | |
| 19 | 15 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.